Genscript Biotech Corporation
GNNSF | OTC
$4.50
+$0.12 (+2.74%)
Nov 2, 2026, 10:19 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 844M | 959.53M | 828.1M | 594.49M | 733.38M | 839.53M | 707.42M | 625.7M | 570.12M | 490.1M | 454.02M |
Cost of Revenue | 405.21M | 406.32M | 368.85M | 322.36M | 365.37M | 429.98M | 396.79M | 321.62M | 257.72M | 207.58M | 167.68M |
Gross Profit | 438.79M | 553.2M | 459.25M | 272.13M | 368.01M | 409.55M | 310.63M | 304.08M | 312.4M | 282.52M | 286.34M |
Operating Income | 125.59M | 255.25M | 179.43M | 9.28M | -184.27M | -415.79M | -483.31M | -437.98M | -404.2M | -379.29M | -272.17M |
Interest Income | 24.12M | 16.93M | 29.61M | 129.44M | 132.77M | 45.68M | 16.64M | 4.25M | 6.38M | 6.46M | 7.93M |
Pretax Income | -589.54M | -470.53M | -42.99M | -170.8M | -234.25M | -350.98M | -446.57M | -431.69M | -596.92M | -517.36M | -274.08M |
Net Income | -636.4M | -532.83M | 3.11B | 2.96B | -177.01M | -95.48M | -184.93M | -226.85M | -403.1M | -358.71M | -182.98M |
Selling & General & Admin | 233.95M | 226.73M | 219.63M | 209.05M | 301.88M | 392.52M | 374.12M | 351.96M | 355.72M | 303.41M | 235.43M |
Research & Development | 79.26M | 71.23M | 60.2M | 53.79M | 250.41M | 432.83M | 419.82M | 390.1M | 360.88M | 358.4M | 323.08M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 313.2M | 297.96M | 279.83M | 262.84M | 552.28M | 825.34M | 734M | 735.72M | 915.7M | 804.06M | 566.06M |
Interest Expense | 14.48M | 8.11M | 8.03M | 8.03M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 51.98M | 99.49M | 92.58M | 88.12M | 135.95M | 174.3M | 162.81M | 168.35M | 196.64M | 167.97M | 124.55M |
Cost & Expenses | 718.41M | 704.28M | 648.67M | 585.2M | 917.65M | 1.26B | 1.13B | 1.06B | 1.17B | 1.01B | 733.74M |
Income Tax Expense | 47.35M | 61.87M | 31.26M | 16.65M | 12.85M | 4.14M | -6.43M | -3.72M | -1.15M | 964K | 2.99M |
Shares Outstanding (Basic) | 2.19B | 2.18B | 1.18B | 2.18B | 2.12B | 1.99B | 2.11B | 2.1B | 2.09B | 2.08B | 1.98B |
Shares Outstanding (Diluted) | 2.19B | 2.23B | 2.16B | 2.18B | 2.12B | 2.11B | 2.11B | 2.1B | 2.09B | 2.09B | 1.98B |
EPS (Basic) | -0.30 | -0.25 | 0 | -0.03 | -0.05 | -0.05 | -0.09 | -0.11 | -0.19 | -0.18 | -0.09 |
EPS (Diluted) | -0.29 | -0.25 | -0.01 | -0.03 | -0.05 | -0.05 | -0.09 | -0.11 | -0.19 | -0.18 | -0.09 |
EBITDA | 198.44M | 317.61M | 237.18M | 70.04M | -122.5M | -358.52M | -430.37M | -388.9M | -362.22M | -341.57M | -234.76M |
EBIT | 125.59M | 255.25M | 179.43M | 9.28M | -184.27M | -415.79M | -483.31M | -437.98M | -404.2M | -379.29M | -272.17M |
Depreciation & Amortization | 72.85M | 62.36M | 57.75M | 60.75M | 61.78M | 57.27M | 52.94M | 49.08M | 41.98M | 37.72M | 37.41M |
Add to Watchlist
Select watchlists to add or remove GNNSF